Custirsen (OGX-011): A second-generation antisense inhibitor of clusterin in development for the treatment of prostate cancer

Future Oncology

Volumn 8, Issue 10, 2012, Pages 1239-1251

  Zielinski, Robert ^a   Chi, Kim N ^b  

^a BRITISH COLUMBIA CANCER AGENCY   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

antisense oligonucleotide; cancer; chaperone protein; clusterin; custirsen; prostate cancer

Indexed keywords

ABIRATERONE ACETATE; ANDROGEN; BEVACIZUMAB; BICALUTAMIDE; CABAZITAXEL; CAMPTOTHECIN; CISPLATIN; CLUSTERIN; CUSTIRSEN; DACARBAZINE; DENOSUMAB; DOCETAXEL; DOXORUBICIN; ENZALUTAMIDE; ETOPOSIDE; FLUOROURACIL; FLUTAMIDE; GEMCITABINE; MITOXANTRONE; PACLITAXEL; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; PROTEIN BAX; RADIOISOTOPE; RADIUM 223; SIPULEUCEL T; TESTOSTERONE; UNCLASSIFIED DRUG; ZOLEDRONIC ACID;

ABLATION THERAPY; ACUTE CORTICAL BLINDESS; ADJUVANT CHEMOTHERAPY; ADVANCED CANCER; APOPTOSIS; APPETITE; ARTHRALGIA; ARTICLE; ASTHENIA; BLINDNESS; BREAST CANCER; BRONCHIOLITIS; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER RESISTANCE; CANCER SURGERY; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CELL SURVIVAL; CHEMOTHERAPY INDUCED ANEMIA; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CHILL; CONSTIPATION; CYTOTOXICITY; DIARRHEA; DRUG ACCUMULATION; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DEVELOPMENT; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG FEVER; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; ERECTILE DYSFUNCTION; FAINTNESS; FATIGUE; FEBRILE NEUTROPENIA; FEVER; GRANULOCYTOPENIA; HEART INFARCTION; HOT FLUSH; HUMAN; HYPOTENSION; IC 50; IMMUNOTHERAPY; IMPOTENCE; IN VITRO STUDY; IN VIVO STUDY; INCONTINENCE; INFUSION RELATED REACTION; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; LYMPHOCYTOPENIA; MULTICENTER STUDY (TOPIC); MYALGIA; NAUSEA; NONHUMAN; OVERALL SURVIVAL; PATIENT CARE; PERIPHERAL EDEMA; PHARMACODYNAMICS; PHARMACOKINETICS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLEURA EFFUSION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATECTOMY; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RASH; RIGOR; SIDE EFFECT; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; STOMATITIS; TESTOSTERONE BLOOD LEVEL; THROMBOCYTOPENIC PURPURA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR LOCALIZATION; TUMOR VOLUME; URINE RETENTION; VOMITING; WEAKNESS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; CLUSTERIN; DRUG APPROVAL; HUMANS; MALE; OLIGONUCLEOTIDES, ANTISENSE; ORCHIECTOMY; PROSTATIC NEOPLASMS; THIONUCLEOTIDES; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84868550507     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.12.129     Document Type: Article

References (65)

1. Miyake H, Muramaki M, Furukawa J et al. Serum level of clusterin and its density in men with prostate cancer as novel biomarkers reflecting disease extension. Urology 75(2), 454-459 (2010).
2. Hoeller C, Pratscher B, Thallinger C et al. Clusterin regulates drug-resistance in melanoma cells. J. Invest. Dermatol. 124(6), 1300-1307 (2005). (Pubitemid 40847419)
3. Xie MJ, Motoo Y, Su SB et al. Expression of clusterin in human pancreatic cancer. Pancreas 25(3), 234-238 (2002).
4. Yang GF, Li XM, Xie D. Overexpression of clusterin in ovarian cancer is correlated with impaired survival. Int. J. Gynecol. Cancer 19(8), 1342-1346 (2009).
5. Bi J, Guo AL, Lai YR et al. Overexpression of clusterin correlates with tumor progression, metastasis in gastric cancer: A study on tissue microarrays. Neoplasma 57(3), 191-197 (2010).
6. Miyake H, Gleave ME, Kamidono S. Overexpression of clusterin in transitional cell carcinoma of the bladder is related to disease progression and recurrence. Urology 59, 150-154 (2002). (Pubitemid 34059338)
7. Pucci S, Mazzarelli P, Nucci C et al. CLU "in and out": Looking for a link. Adv. Cancer Res. 105, 93-113 (2009).
8. Poon S, Easterbrook-Smith SB, Rybchyn MS et al. Clusterin is an ATP-independent chaperone with very broad substrate specificity that stabilizes stressed proteins in a folding-competent state. Biochemistry 39(51), 15953-15960 (2000). (Pubitemid 32038257)
9. Gleave M, Jansen B. Clusterin and IGFBPs as antisense targets in prostate cancer. Ann. NY Acad. Sci. 1002, 95-104 (2003). (Pubitemid 38253334)
10. Chi K, Hotte SJ, Yu EY et al. Randomized Phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancer. J. Clin. Oncol. 28(27), 4247-4254 (2010).
11. Tannock IF, de Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 351(15), 1502-1512 (2004). (Pubitemid 39315317)
12. Tannock IF, Osoba D, Stockler MR et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative end points. J. Clin. Oncol. 14(6), 1756-1764 (1996). (Pubitemid 26185452)
13. de Bono JS, Oudard S, Ozguroglu M et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomised open-label trial. Lancet 376(9747), 1147-1154 (2010).
14. Saad F, Gleason DM, Murray R et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormonerefractory metastatic prostate carcinoma. J. Natl Cancer Inst. 94(19), 1458-1468 (2002).
15. Smith MR, Saad F, Coleman R et al. Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: Results of a Phase 3, randomised, placebo-controlled trial. Lancet 379(9810), 39-46 (2012).
16. Kantoff PW, Higano CS, Shore ND et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363(5), 411-422 (2010).
17. de Bono JS, Logothetis CJ, Molina A et al. Abiraterone and increased survival in metastatic prostate cancer. N. Engl. J. Med. 364(21), 1995-2005 (2011).
18. Scher H, Fizazi K, Saad F et al. Effect of MDV3100, an androgen receptor signaling inhibitor (ARSI), on overall survival in patients with prostate cancer post docetaxel: Results from the Phase III AFFIRM study. J. Clin. Oncol. 30(Suppl. 5), Abstract LBA1 (2012).
19. Parker C, Nilsson S, Heinrich D et al. Updated analysis of the Phase III, doubleblind, randomized, multinational study of radium-223 chloride in castration-resistant prostate cancer (CRPC) patients with bone metastases (ALSYMPCA). J. Clin. Oncol. 30(Suppl.), Abstract LBA4512 (2012).
20. Siegel R, Desantis C, Virgo K et al Cancer treatment and survivorship statistics, 2012. CA Cancer J. Clin. 62(4), 220-241 (2012).
21. Wong P, Borst DE, Farber D et al. Increased TRPM-2/clusterin mRNA levels during the time of retinal degeneration in mouse models of retinitis pigmentosa. Biochem. Cell. Biol. 72(9-10), 439-446 (1994).
22. Zoubeidi A, Zardan A, Wiedmann RM et al. Hsp27 promotes insulin-like growth factor-I survival signaling in prostate cancer via p90Rsk-dependent phosphorylation and inactivation of BAD. Cancer Res. 70(6), 2307-2317 (2010).
23. Zhang Q, Zhou W, Kunda S. The leader sequence triggers and enhances several functions of clusterin and is instrumental in the progression of human prostate cancer in vivo and in vitro. Br. J. Urol. Int. 98, 452-460 (2006).
24. Leskov KS, Klokov DY, Li J. Synthesis and functional analyses of nuclear clusterin, a cell death protein. J. Biol. Chem. 278, 11590-11600 (2003). (Pubitemid 36792721)
25. Loison F, Debure L, Nizard P et al. Up-regulation of the clusterin gene after proteotoxic stress: Implication of HSF1- HSF2 heterocomplexes. Biochem. J. 395(1), 223-231 (2006).
26. Michel D, Chatelain G, North S. Stressinduced transcription of the clusterin/apoJ gene. Biochem. J. 328, 45-50 (1997).
27. Humphreys DT, Carver JA, Easterbrook- Smith SB. Clusterin has chaperone-like activity similar to that of small heat shock proteins. J. Biol. Chem. 274, 6875-6881 (1999).
28. Miyake H, Nelson C, Rennie PS et al. Acquisition of chemoresistant phenotype by overexpression of the antiapoptotic gene testosterone-repressed prostate message-2 in prostate cancer xenograft models. Cancer Res. 60(9), 2547-2554 (2000). (Pubitemid 30262451)
29. Sensibar JA, Sutkowski DM, Raffo A. Prevention of cell death induced by tumor necorsis factor a in LNCaP cells by overepxression of sulfated gylocprotein-2 (Clusterin). Cancer Res. 55, 2431-2437 (1995).
30. Zellweger T, Chi K, Miyake H. Enhanced radiation sensitivity in prostate cancer by inhibition of the cell survival protein clusterin. Clin. Cancer Res. 8, 3276-3284 (2002). (Pubitemid 35155041)
31. Miyake H, Chi KN, Gleave ME. Antisense TRPM-2 oligodeoxynucleotides chemosensitize human androgen-independent PC-3 prostate cancer cells both in vitro and in vivo. Clin. Cancer Res. 6, 1655-1663 (2000). (Pubitemid 30305057)
32. Zhang H, Kim JK, Edwards CA. Clusterin inhibitis apoptosis by interacting with activated Bax. Nat. Cell Biol. 7, 909-915 (2005). (Pubitemid 41486292)
33. Zhong B, Sallman DA, Gilvary DL et al. Induction of clusterin by AKT - role in cytoprotection against docetaxel in prostate tumor cells. Mol. Cancer Ther. 9(6), 1831-1841 (2010).
34. Song H, Zhang B, Watson MA et al. Loss of Nkx3.1 leads to the activation of discrete downstream target genes during prostate tumorigenesis. Oncogene 28(37), 3307-3319 (2009).
35. July LV, Beraldi E, So A. Nucleotide-based therapies targeting clusterin chemosensitize human lung adenocarcinoma cells both in vitro and in vivo. Mol. Cancer Ther. 3, 223-232 (2004). (Pubitemid 39193697)
36. Patterson SG, Wei S, Chen X et al. Novel role of Stat1 in the development of docetaxel resistance in prostate tumor cells. Oncogene 25(45), 6113-6122 (2006). (Pubitemid 44562409)
37. Sowery RD, Hadaschik BA, So AI et al. Clusterin knockdown using the antisense oligonucleotide OGX-011 re-sensitizes docetaxel-refractory prostate cancer PC-3 cells to chemotherapy. BJU Int. 102(3), 389-397 (2008). (Pubitemid 352019195)
38. Chen Q, Wang Z, Zhang K et al. Clusterin confers gemcitabine resistance in pancreatic cancer. World J. Surg. Oncol. 9, 59 (2011).
39. Lee CH, Jin RJ, Kwak C et al. Suppression of clusterin expression enhanced cisplatininduced cytotoxicity on renal cell carcinoma cells. Urology 60(3), 516-520 (2002). (Pubitemid 35292196)
40. Lourda M, Trougakos IP, Gonos ES. Development of resistance to chemotherapeutic drugs in human osteosarcoma cell lines largely depends on up-regulation of Clusterin/Apolipoprotein J. Int. J. Cancer 120(3), 611-622 (2007). (Pubitemid 44969033)
41. Miyake H, Hara I, Kamidono S et al. Synergistic chemsensitization and inhibition of tumor growth and metastasis by the antisense oligodeoxynucleotide targeting clusterin gene in a human bladder cancer model. Clin. Cancer Res. 7(12), 4245-4252 (2001). (Pubitemid 34044651)
42. Wei L, Xue T, Wang J et al. Roles of clusterin in progression, chemoresistance and metastasis of human ovarian cancer. Int. J. Cancer 125(4), 791-806 (2009).
43. Crooke ST. Therapeutic applications of oligonucelotides. Annu. Rev. Pharmacol. Toxicol. 32, 329-376 (1992).
44. Saijo Y, Perlaky L, Wang H. Pharmacokinetics, tissue distribution, and stability of antisense oligodeoxynucleotide phosphorothioate ISIS 3466 in mice. Oncol. Res. 6, 243-249 (1994). (Pubitemid 24329591)
45. Zellweger T, Miyake H, Cooper S. Antitumor activity of antisense clusterin oligonucleotides is improved in vitro and in vivo by incorporation of 2́-O-(2-methoxy)ethyl chemistry. J. Pharmacol. Exp. Ther. 298, 934-940 (2001). (Pubitemid 32761906)
46. Henry S, Stecker K, Brooks D. Chemically modified oligonucleotides exhibit decreased immune stimualtion in mice. J. Pharmacol. Exp. Ther. 292, 468-479 (2000).
47. Geary RS, Yu RZ, Watanabe T et al. Pharmacokinetics of a tumor necrosis factor-a phosphorothioate 2́-O-(2-methoxyethyl) modified antisense oligonucleotide: Comparison across species. Drug Metab. Dispos. 31(11), 1419-1428 (2003). (Pubitemid 37310332)
48. Chi K, Eisenhauer E, Fazli L et al. A Phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2́methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer. J. Nat. Cancer Inst. 97(17), 1287-1296 (2005). (Pubitemid 41535369)
49. Cao C, Shinohara ET, Li H. Clusterin as a therapeutic target for radiation sensitization in a lung cancer model. Int. J. Radiat. Oncol. Biol. Phys. 63, 1228-1236 (2005). (Pubitemid 41505304)
50. Muramaki M, So A, Hayashi N et al. Chemosensitization of gemcitabine-resistant human bladder cancer cell line both in vitro and in vivo using antisense oligonucleotide targeting the anti-apoptotic gene, clusterin. BJU Int. 103(3), 384-390 (2009).
51. Chi K, Siu LL, Hirte H et al. A Phase I study of OGX-011, a 2'methoxyethyl phosphorothioate antisense to clusterin, in combination with docetaxel in patients with advanced cancer. Clin. Cancer Res. 14(3), 833-839 (2008). (Pubitemid 351231167)
52. Chi KN, Goldenberg L, Kollmannsberger C et al. A Phase II neoadjuvant study of OGX-011, a 2́methoxyethyl phosphorothioate antisense to clusterin, in patients with prostate cancer prior to prostatectomy. Presented at: 2008 Genitourinary Cancers Symposium. San Francisco, CA, USA, 14-16 February 2008 (Abstract 167).
53. Laskin JJ, Nicholas G, Lee C et al. Phase I/II trial of custirsen (OGX-011), an inhibitor of clusterin, in combination with a gemcitabine and platinum regimen in patients with previously untreated advanced non-small cell lung cancer. J. Thorac. Oncol. 7(3), 579-586 (2012).
54. Sederholm C. Gemcitabine versus gemcitabine/carboplatin in advanced non-small cell lung cancer: Preliminary findings in a Phase III trial of the Swedish Lung Cancer Study Group. Semin. Oncol. 29(3 Suppl. 9), S50-S54 (2002).
55. Mazzanti P, Massacesi C, Rocchi MB et al. Randomized, multicenter, Phase II study of gemcitabine plus cisplatin versus gemcitabine plus carboplatin in patients with advanced non-small cell lung cancer. Lung Cancer 41(1), 81-89 (2003). (Pubitemid 36765487)
56. Zatloukal P, Petruzelka L, Zemanova M et al. Gemcitabine plus cisplatin vs. gemcitabine plus carboplatin in stage IIIb and IV non-small cell lung cancer: A Phase III randomized trial. Lung Cancer 41(3), 321-331 (2003). (Pubitemid 36970188)
57. Scagliotti GV, De Marinis F, Rinaldi M et al. Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer. J. Clin. Oncol. 20(21), 4285-4291 (2002). (Pubitemid 35266288)
58. Scagliotti GV, Parikh P, von Pawel J et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advancedstage non-small-cell lung cancer. J. Clin. Oncol. 26(21), 3543-3551 (2008).
59. Sandler A, Gray R, Perry MC et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med. 355(24), 2542-2550 (2006). (Pubitemid 44917502)
60. Chia S, Dent S, Ellard S et al. Phase II trial of OGX-011 in combination with docetaxel in metastatic breast cancer. Clin. Cancer Res. 15(2), 708-713 (2009).
61. Saad F, Hotte S, North S et al. Randomized Phase II trial of custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c. Clin. Cancer Res. 17(17), 5765-5773 (2011).
62. Michels J, Montemurro T, Murray N et al. First- and second-line chemotherapy with docetaxel or mitoxantrone in patients with hormone-refractory prostate cancer: Does sequence matter? Cancer 106(5), 1041-1046 (2006).
63. Zupancic M, Shah PC, Shah-Khan F. Gemcitabine-associated thrombotic thrombocytopenic purpura. Lancet Oncol. 8(7), 634-641 (2007). (Pubitemid 46995635)
64. Pippitt CH Jr, Muss HB, Homesley HD et al. Cisplatin-associated cortical blindness. Gynecol. Oncol. 12(2 Pt 1), 253-255 (1981). (Pubitemid 12239330)
65. Berman IJ, Mann MP. Seizures and transient cortical blindness associated with cisplatinum (II) diamminedichloride (PDD) therapy in a thirty-year-old man. Cancer 45(4), 764-766 (1980) (Pubitemid 10174622)